Recovery & Repair
Mobility and repair
A thymosin beta-4 fragment used to support injury recovery, flexibility and circulation.
Ships as a freeze-dried powder. Need water to mix it? Add Reconstitution Solution.
The science
Evidence level
1/5
Preclinical
Full-length thymosin β4 has phase 2 human data; TB-500 itself, a related fragment, has not been studied in controlled human trials.
4–6×2
more endothelial-cell migration with thymosin β4 in vitro
~1 month4
faster ulcer healing in two phase 2 trials, among patients who healed
1,260 mg5
top IV dose of thymosin β4, well tolerated in healthy volunteers
Mechanism of action
Targets & pathways
Thymosin β4 binds G-actin, controlling the cytoskeletal remodelling that lets cells crawl into damaged tissue1.
It increased the directional migration of human endothelial cells four- to six-fold, a first step in new vessel formation2.
Thymosin β4 also raised production of matrix metalloproteinases, enzymes that open the basement membrane during angiogenesis2.
In normal, aged, diabetic and steroid-treated animals, it accelerated healing of full-thickness skin wounds4.
What the research shows
Thymosin β4 accelerated dermal healing in rats and mice, including diabetic, aged and steroid-treated models.
Endothelial cells migrated four- to six-fold more and produced more matrix-remodelling enzymes.
Single and 14-day intravenous dosing from 42 to 1,260 mg was well tolerated in a placebo-controlled study, with no dose-limiting toxicity.
A topical full-length thymosin beta-4 study randomized 73 venous-ulcer patients and reported exploratory healing findings.
The effect of thymosin treatment of venous ulcers.
Annals of the New York Academy of Sciences · 2010
PubMed ↗ (opens in a new tab)A healthy-volunteer intravenous study assessed full-length thymosin beta-4 tolerability and pharmacokinetics.
A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Annals of the New York Academy of Sciences · 2010
PubMed ↗ (opens in a new tab)Reviews thymosin β4’s actin-binding, cell-migration and regenerative biology.
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
Expert opinion on biological therapy · 2012
PubMed ↗ (opens in a new tab)Questions
The name is used inconsistently. FDA describes a fragment; the catalog also contains a full-length source comment. Ask the pharmacy for the actual identity.
They explain the borrowed scientific rationale, with explicit limits on applying them to a fragment.
The parent thymosin literature emphasizes actin-associated cell movement; BPC-157 has fibroblast and vascular-signalling work. Neither establishes broad recovery efficacy for these compounded products.
No. It tested a topical full-length preparation in a defined clinical setting.
The catalog identity is ambiguous; assigning parent or fragment values would imply certainty that is not present.
Recovery & Repair
Recovery & Repair
Recovery & Repair
Recovery & Repair